Show simple item record

dc.contributor.authorMazón Ortiz, Gabriel
dc.contributor.authorCerda Mejía, Galo
dc.contributor.authorGutiérrez Morales, Eberto
dc.contributor.authorDiéguez Santana, Karel
dc.contributor.authorRuso, Juan M.
dc.contributor.authorGonzález Díaz, Humberto
dc.date.accessioned2024-01-22T16:04:01Z
dc.date.available2024-01-22T16:04:01Z
dc.date.issued2023-10-28
dc.identifier.citationDiseases 11(4) : (2023) // Article ID 153es_ES
dc.identifier.issn2079-9721
dc.identifier.urihttp://hdl.handle.net/10810/64198
dc.description.abstractLeishmaniasis is a neglected tropical illness with a wide variety of clinical signs ranging from visceral to cutaneous symptoms, resulting in millions of new cases and thousands of fatalities reported annually. This article provides a bibliometric analysis of the main authors’ contributions, institutions, and nations in terms of productivity, citations, and bibliographic linkages to the appli- cation of nanoparticles (NPs) for the treatment of leishmania. The study is based on a sample of 524 Scopus documents from 1991 to 2022. Utilising the Bibliometrix R-Tool version 4.0 and VOSviewer software, version 1.6.17 the analysis was developed. We identified crucial subjects associated with the application of NPs in the field of antileishmanial development (NPs and drug formulation for leishmaniasis treatment, animal models, and experiments). We selected research topics that were out of date and oversaturated. Simultaneously, we proposed developing subjects based on multiple analyses of the corpus of published scientific literature (title, abstract, and keywords). Finally, the technique used contributed to the development of a broader and more specific “big picture” of nanomedicine research in antileishmanial studies for future projects.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/es/
dc.subjectnanomedicinees_ES
dc.subjectbibliometric analysises_ES
dc.subjectnetwork analysises_ES
dc.subjectparasite diseaseses_ES
dc.subjectleishmaniasis treatmentes_ES
dc.subjectantiprotozoal agentses_ES
dc.titleTrends in Nanoparticles for Leishmania Treatment: A Bibliometric and Network Analysises_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.date.updated2023-12-22T13:45:17Z
dc.rights.holder© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/).es_ES
dc.relation.publisherversionhttps://www.mdpi.com/2079-9721/11/4/153es_ES
dc.identifier.doi10.3390/diseases11040153
dc.departamentoesQuímica Orgánica e Inorgánica
dc.departamentoeuKimika Organikoa eta Ez-Organikoa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/).
Except where otherwise noted, this item's license is described as © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/).